Combinatorial Protein Transfer for Cancer Therapeutics

用于癌症治疗的组合蛋白转移

• 批准号: 6771867
• 负责人: AOSHUANG CHEN
• 金额: $ 27.74万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6771867
• 关键词: CD40 molecule; T cell receptor; T lymphocyte; antigen presenting cell; antineoplastics; biological signal transduction; carcinoma; cell cycle; chimeric proteins; combination cancer therapy; cytotoxic T lymphocyte; dendritic cells; drug interactions; immune tolerance /unresponsiveness; laboratory mouse; leukocyte activation /transformation; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; neoplastic cell; nonhuman therapy evaluation; tissue /cell culture

This proposal centers upon the application of a novel Fc fusion protein transfer method that we have recently developed to combination therapy for cancer. The configuration of the proposed studies has been based upon three hypotheses. First, in addition to converting tumor cells to professional APCs via T cell costimulator transfer in order to directly activate CTLs (direct priming), anti-tumor immunity may be more efficiently elicited by simultaneously promoting bystander host antigen- presenting cells (APCs), dendritic cells (DCs) in particular, to prime CTLs (indirect priming). Hence, one can begin to think beyond T cells per se and look to the potentiation of DC function in parallel. Second, in light of the short life span of DCs in vivo, anti-tumor immunity may be enhanced by promoting DC longevity in tumor microenvironment, maximizing the extent of T cell activation inducible by limited number of tumor antigen- pulsed DCs. Third, anti-tumor immunity may be further optimized by, in addition to improving DC longevity, simultaneously promoting the recruitment of DCs to tumor site. Driven by these hypotheses, our preliminary data demonstrate the feasibility of eliciting a systemic, long-term anti-tumor immunity via in situ protein transfer of a "tetra-costimulator" combination, chosen to activate T cells as well as APCs. Building upon these preliminary data, the proposed studies seek to exploit our Fc fusion protein transfer method as a means to deepen our understanding of the regulations of T cell activation and DC longevity and, in turn, use the gained insights to optimize anti- tumor immunity in vivo. The three specific aims are: 1) To assess synergy/cooperation among T cell costimulators, spatial requirements among costimulatory signals themselves as well as between costimulatory and antigenic signals, and costimulator synergy in promoting T cell mitosis; 2) To determine the quantitative interplay between DC activators and DC inhibitors in modulating DC longevity; and 3) To assess the relevance of costimulator synergy, enhanced DC longevity, and increased DC quantity to more effective anti-tumor response.

该建议集中在我们最近开发的一种新的Fc融合蛋白转移方法在癌症联合治疗中的应用。 拟议研究的配置基于三个假设。 首先，除了通过T细胞共刺激分子转移将肿瘤细胞转化为专职APC以直接激活CTL（直接引发）之外，还可以通过同时促进旁观者宿主抗原呈递细胞（APC），特别是树突状细胞（DC）引发CTL（间接引发）来更有效地引发抗肿瘤免疫。 因此，人们可以开始超越T细胞本身来思考，并平行地观察DC功能的增强。 其次，鉴于DC在体内的寿命较短，可以通过促进DC在肿瘤微环境中的寿命，最大化有限数量的肿瘤抗原脉冲DC诱导的T细胞活化程度来增强抗肿瘤免疫。 第三，除了改善DC寿命之外，还可以通过同时促进DC向肿瘤部位的募集来进一步优化抗肿瘤免疫。 在这些假设的驱动下，我们的初步数据证明了通过选择激活T细胞以及APC的“四共刺激物”组合的原位蛋白转移来引发系统性的长期抗肿瘤免疫的可行性。 在这些初步数据的基础上，提出的研究试图利用我们的Fc融合蛋白转移方法作为加深我们对T细胞活化和DC寿命的调节的理解的手段，并且反过来，使用所获得的见解来优化体内抗肿瘤免疫。 三个具体目标是：1）评估T细胞共刺激分子之间的协同/合作、共刺激信号本身之间以及共刺激信号和抗原信号之间的空间要求，以及共刺激分子在促进T细胞有丝分裂中的协同作用; 2）确定DC激活剂和DC抑制剂在调节DC寿命中的定量相互作用;和3）评估共刺激物协同作用、增强的DC寿命和增加的DC量与更有效的抗肿瘤应答的相关性。